RheumNow Live 2023 Pre-Learn Survey

Please complete this series of True-False questions to prepare for RheumNow.live on March 18th and 19th.  Each Question has a Teaching Point evident by your answer – either True (evident as is) or False (the converse is true).  This “Pre-learn” survey will take 10 minutes. Lastly, you can also download the reading material each speaker has chosen for you to read prior to the meeting by clicking on the RheumNow Live Logo at the end of the survey.

Higher rates of pre-eclampsia, cesarean section and preterm birth are seen with PsA pregnancies.

Pregnant psoriatic arthritis patients are likely to increase or worsen disease activity after delivery compared to during pregnancy.

Hydroxychloroquine should be discontinued during pregnancy and breastfeeding

Hydroxychloroquine is FDA-approved for SLE, discoid lupus and rheumatoid arthritis.

Guidelines suggest PsA remission should be assessed by DAPSA or MDA.

The surface of hand/palm represents ~1% of your body surface area (BSA) when assessing the extent of psoriasis.

Pre-clinical RA patients produce increased ACPA in the lung.

One successful clinical trial demonstrating equivalence of biosimilar to its reference product can result in FDA approval of the biosimilar for multiple indications.

Amongst the oral DMARDs, methotrexate has the least effect on vaccine responses.

Assessing GCA, the MRA is better at damage, while FDA-PET better detects activity/inflammation.

Cardiac involvement is more common in GPA than EGPA

In the USA, ~20% have chronic low back pain

First degree relatives of AS patients have a 4-11% risk of developing AS

Between MRI and CT scan, MRI has the best accuracy in diagnosing sacroiliitis.

Over 5 years, 16% of nonradiographic AxSpA will progress to radiographic AxSpA

Compared to available biologics, JAK inhibitors are better at controlling psoriasis, more so than psoriatic arthritis.

Deucravacitinib is more effective than apremilast in treating plaque psoriasis

Treatment with IV rituximab reduces circulating BAFF levels (B Cell Activating Factor)

Interferon alpha is the biologic target of belimumab

In 2021 ACR guidelines, low dose ASA is recommended for GCA patients with vertebral or carotid artery involvement.

It looks like you can vote in this survey!

Click on the button to cast your vote.

Vote!
17 March 2023
Faith and Miracle Larry

This week on the podcast, Dr. Jack Cush recalls what life was like early on during COVID, from March to June of 2020.  During this time, his close friend, Larry, contracted COVID-19 and was hospitalized, intubated and put on mechanical ventilation for nearly 2 months. Larrys recovery from the grave became the "Miracle Larry" story that will be told by Larry Kelly himself, the keynote speaker at RheumNow Live 2023 on Saturday March 18th.

Come here Miracle Larry at RNL23.

You can also read about Miracle Larry here:

Faith and Miracle Larry

Transcriptomic studies of Rx Refractory #RA pts shows increased gene expression of plasmacytoid dendritic cells (pDC) (r

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Transcriptomic studies of Rx Refractory #RA pts shows increased gene expression of plasmacytoid dendritic cells (pDC) (reflecting expansion of pDC precursors) correlated well w/ Rx resistance. Type I IFN negatively correlated w pre-DC gene expression https://t.co/japvTnuTNu https://t.co/ad6ofbg3cO
Links
https://bit.ly/3mM2lTb
16 March 2023
2022 EULAR Recommendations for ANCA-associated Vasculitis

EULAR has published the 2022 update on recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).

AAV recommendations were last published in 2016, and since, research and clinical trials have advanced our understanding of AAV.  A EULAR task force of 20 experts from 16 countries, reviewed the literature and developed four overarching principles and 17 recommendations.

16 March 2023
Polypharmacy Increased in Psoriatic Arthritis

Psoriatic arthritis (PsA) is plagued by obesity, depression and increased comorbidities; now it appears that polypharmacy adds to the burden of managing PsA.

A study of 11,984 PsA patients in the German BARMER health insurance database from 2021 compared medicines and comorbidities with sex-matched and age-matched controls without inflammatory arthritis. Polypharmacy was defined as ≥5 concomitant drugs.

Compared to controls, PsA patients were prescribed significantly more medications compared to controls; especially for these drug classes:

Open-label trial of Guselkumab (IL-23 inhib) in 20 moderate-to-severe hidradenitis suppurativa (HS) pts saw 65% with HiS

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Open-label trial of Guselkumab (IL-23 inhib) in 20 moderate-to-severe hidradenitis suppurativa (HS) pts saw 65% with HiSCR response at wk 16. Yet phase IIB NOVA PBO-RCT showed GUS HiSCR response 45–51% (vs 39% PBO). GUS may only benefit subgroup of HS https://t.co/OxtFfyRMFk https://t.co/hnQyU0VWxg
Links
https://bit.ly/3mZIjov

Cost-Effective Use of Biological and Targeted Synthetic DMARDs An international task force of experts have developed e

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Cost-Effective Use of Biological and Targeted Synthetic DMARDs An international task force of experts have developed evidence-based points to consider regarding the cost-effective use of b/tsDMARDs in the treatment of inflammatory rheumatic diseases. https://t.co/jpxQggd89T https://t.co/zjer5QTN3C
Links
https://bit.ly/3JLjJkg

Congratulations to Dr. Georg Schett (University of Erlangen) upon receiving the 2023 Gottfried Wilhelm Leibniz Prize - h

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Congratulations to Dr. Georg Schett (University of Erlangen) upon receiving the 2023 Gottfried Wilhelm Leibniz Prize - highest honor from the DFG, German Research Foundation. Dr. Schett is famed for research on inflammation, autoimmunity & osteoimmunology https://t.co/Wq0EvhtvLW https://t.co/AWwCVCt4cm
Links
https://bit.ly/3yOfe1L
Subscribe to
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×